Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Santarus, Inc. (SNTS)
Santarus Receives FDA Approval of UCERIS (Budesonide) for the Induction of Remission in Patients with Active, Mild to Moderate Ulcerative Colitis
January 15, 2013 09:00 am ET
Martha Hough - VP Finance & Investor Relations
Gerry Proehl - Director, President and Chief Executive Officer
Debbie Crawford - Senior Vice President, Chief Financial Officer, Treasurer and Secretary
Bill Denby - Senior Vice President, Commercial Operations
Wendell Wierenga - Executive Vice President, Research and Development
Scott Henry - Roth Capital
David Amsellem - Piper Jaffray
Daniel Chang - Stifel
Brian Lian - SunTrust
Previous Statements by SNTS
» Santarus' CEO Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
» Santarus' CEO Discusses Q3 2012 Results - Earnings Call Transcript
» Santarus' CEO Presents at UBS Global Life Sciences Conference (Transcript)
Thank you. Ms. Martha Hough. You may begin your conference.
Thank you, Melissa. Good morning, and welcome to today's call. This is Martha Hough, Vice President of Finance and Investor Relations.
Joining me on the call today are Gerry Proehl, President and Chief Executive Officer; Debra Crawford, Senior Vice President and Chief Financial Officer; Bill Denby, Senior Vice President of Commercial Operations. Dr. Wendell Wierenga, Executive Vice President of Research and Development will also be available during the question-and-answer session.
Yesterday after market closed, Santarus issued a press release announcing FDA approval of UCERIS, extended release tablets. This press release is available on our website at www.santarus.com. We will also make a replay of today's call available for the next two weeks on the Investor Relations section of our website.
Please keep in mind that risks and uncertainties involved in the company's business may affect the matters referred to in forward-looking statements made by management during today's call. As a result, the company's performance may differ from those expressed in or indicated by such forward-looking statements, which are qualified in their entirety by the cautionary statements contained in the press release and the company's Securities and Exchange Commission filings.
The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast on January 15, 2013. Santarus undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call.
In this call, when talking about our company's financial outlook, we will also discuss adjusted EBITDA, a non-GAAP financial measure. You can find the reconciliation of adjusted EBITDA to GAAP net income in our press release issued yesterday.
I'll now turn the call over to Gerry Proehl.
Thank you, Martha, and welcome to this morning's call. Yesterday FDA approval of UCERIS extended release tablets of the induction of remission of active, mild to moderate ulcerative colitis is exciting news and gives us strong momentum at the start of the New Year. We are very pleased to be preparing to launch UCERIS, an important new treatment for the active stage of mild to moderate ulcerative colitis to patients and gastroenterologists. We believe 2013 is shaping up to be another very successful year for Santarus.
UCERIS contains budesonide a locally acting steroid in an oral utilizing MMX colonic delivery technology, designed to release budesonide throughout the calling. In clinical testing UCERIS achieved statistical significant results for the induction of remission of ulcerative colitis over eight weeks compared to placebo.
In two pivotal studies and our 12-month extended use study, the frequency of treatment related adverse events for UCERIS was similar to placebo. We believe UCERIS is uniquely positioned to fill a gap in the treatment paradigm to patient suffering acute mild to moderate ulcerative colitis.
Our commercial group has been focused on preparing for the launch of UCERIS. Bill Denby will review our progress in expanding our sales organization and describe some of our upcoming promotional initiatives later in the call. We expect to complete the manufacturing activities related to labeling and final packaging over the next eight weeks and our planning for the commercial launch of UCERIS in March.
We believe, our strategic plan to prepare Santarus for significant future growth continues to show positive results. To that end, we expect to meet or exceed our full year guidance for 2012, and we are introducing what we believe is a strong 2013 financial outlook, which include substantial growth in revenues and profits over our current guidance for 2012.
I'll now turn the call over to Debbie Crawford to provide the details of our 2012 and 2013 financial guidance. Deb?
Thank you, Gerry, and thank you to everyone for joining our call. As Gerry said, for 2012, we expect to meet or exceed the guidance that we provided on our third quarter financial results call on November 7th.
As a reminder, our guidance includes total revenues of approximately $210 million. Net income of approximately $12 million to $14 million, which includes a total of $14 million in expense for success-based regulatory and clinical milestones and adjusted EBITDA of approximately $29 million to $32 million.
Today, we are pleased to introduce our financial outlook for full year 2013, which includes significant top line growth coupled with bottom line expansion. Our estimates are total revenues of approximately $320 million to $325 million, net income of approximately $50 million to $54 million and adjusted EBITDA of approximately $73 million to $79 million.
Additional details on selected estimated expenses for 2013 are as follows. License fees will include a $5 million expense for a success-based milestone assuming FDA acceptance for review of the RUCONEST Biologics License Application. R&D expenses of approximately $34 million to $38 million, and SG&A expenses of approximately $131 million to $134 million, which include an incremental estimated $38 million to $40 million to fund the sales force expansion of 85 sales reps and promotional and other costs related to the UCERIS launch and ZEGERID re-launch.